-Boston Medical Group Telemedicine Patient\u00a0<\/strong><\/p>\n Importantly, TRT does not increase the risk of prostate cancer.<\/em><\/strong> Putative risks include edema and worsening of sleep apnea<\/a>. Several recent reports have also indicated that TRT may produce cardiovascular (CV) risks, while others report no risk or even benefit\u2026\u201d<\/p>\n * https:\/\/pubmed.ncbi.nlm.nih.gov\/25898953\/<\/a><\/p>\n It was in the early 1940s when it was discovered the male hormone testosterone can feed the growth of prostate cancer. This can also be further proved by the fact that hormone therapy for prostate cancer is a treatment that stops the male hormone testosterone from being produced or reaching prostate cancer cells. Androgens stimulate prostate cancer cells to grow, and testosterone is one of the two main androgens in the body. And if you\u2019re receiving or thinking of getting hormone replacement therapy, it can be spooky to learn while testosterone is vital to the development of generally masculine characteristics in males, it also stokes the growth of prostate cancer cells. It can even make you worried if might increase your risk of developing prostate cancer.<\/p>\n Research has challenged the link between testosterone and prostate cancer in recent years. While there is still a lot that needs to be studied on whether testosterone therapy is safe for men with a history of prostate cancer, there have been studies that found testosterone treatment does not increase a man’s risk of developing prostate cancer<\/strong>. For example, if a person is diagnosed with prostate cancer while taking testosterone, it\u2019s not a cause-and-effect relationship. In fact, a new study published in European Urology found that men with the lowest levels of testosterone had a 23% reduced risk of developing prostate cancer. While, again, further studies are needed regarding the link between hormone therapy and prostate cancer, existing evidence suggests that testosterone therapy can be safe in some men who not only have low testosterone but have completed prostate cancer treatment and are therefore at lower risk for recurrence.<\/p>\n A Preeminent Medical Expert on TRT & Cancer Risks<\/strong><\/p>\n \u201cAbraham Morgentaler, MD, explains new concepts that could subvert the long-held belief that high levels of testosterone exacerbate prostate cancer growth. He discusses the androgen saturation model, as well as the benefits of testosterone therapy for patients\u2019 quality of life.<\/p>\n General attitudes in the urologic community have long maintained that high testosterone exacerbates prostate cancer (PCa), low testosterone is protective, and raising testosterone levels in men with PCa will enable tumor growth. However, these assumptions may be flawed.<\/p>\n In the 1940s, Huggins and Hodges found that\u00a0giving men with bony metastases testosterone caused acid phosphatase levels to rise<\/a>. They concluded that high testosterone was dangerous for PCa patients. However, this study only reported results for 2 men, one of whom was castrated. This means\u00a0that the prohibition against T therapy in men with prostate cancer\u00a0originated from observations in one non-castrated patient<\/a>. Later, many researchers looked for a link between high testosterone and PCa, but found no conclusive results. However,\u00a0data does show<\/a>\u00a0that low testosterone does not protect men from developing PCa.<\/p>\n One concept subverting this long-standing assumption is a saturation model. This concept dictates that PCa growth is sensitive to variations in testosterone levels at the low levels, but this sensitivity lessens at higher testosterone levels<\/a>. According to this model, depriving PCa of testosterone can cause tumor death. However, testosterone only exerts a prostatic effect by binding to the androgen receptor (AR). Once serum testosterone concentrations reach maximal androgen-AR binding, or a saturation point, increasing testosterone will not cause tumors to grow.\u201d<\/em><\/strong><\/p>\n ** https:\/\/grandroundsinurology.com\/testosterone-therapy-in-men-with-advanced-prostate-cancer<\/a><\/p>\n https:\/\/player.vimeo.com\/video\/340896194<\/a><\/p>\n An Oncologist on TRT & Cancer Treatments<\/strong><\/p>\n \u201cTestosterone is usually viewed as a fuel for prostate cancer. Consequently, most researchers are reluctant to explore it as potential therapy. However, Johns Hopkins cancer researcher, Dr. Samuel Denmeade, took a page right out of cancer\u2019s playbook, and figured out what prostate cancer cells were doing to survive hormonal therapy and then beat them their own game. After prolonged treatment with testosterone-blocking drugs, prostate cancer cells adapted to living with low levels of the hormone by ramping up the activity along with the amount of receptors within the cell surface to suck up every bit of testosterone available.<\/p>\n With prostate cancer cells in this state, adapted to an environment with low levels of testosterone, Denmeade wondered what would happen if he flooded the cancer cells with a short burst of high-dose testosterone, using the hormone like a drug. \u201cIf we give testosterone acutely through injection to cause a sharp rise in the hormone, prostate cancer cells won\u2019t like that, and some will die,\u201d says Denmeade. \u201cProstate cancer cells might be killed by the hormone shock, and the cells that survived would make fewer receptors, making prostate cancer cells vulnerable once again to hormone-lowering therapies.\u201d At first glance, it seems paradoxical to give testosterone to a prostate cancer patient, but Denmeade and Isaacs say this approach is very different from the chronic, ongoing supply of testosterone that naturally occurs in men or testosterone replacement therapy. \u201cIt\u2019s pharmacologic testosterone, not physiological testosterone,\u201d says Isaacs.<\/p>\n Prostate cancer cells are not expecting an intense dose of testosterone, and they don\u2019t know that it\u2019s a short burst. Cancer cells that survive will adapt again, this time turning down the activity of those cell surface testosterone receptors. \u201cThey will downregulate their receptors at a time when the drug is wearing off, so we will see a period of low testosterone, low receptor, and that\u2019s not good for cancer cells,\u201d says Denmeade. As the cells are continually challenged with these short bursts of testosterone, they are constantly adapting levels of cell surface receptors up and down. \u201cWe are taking the cancer cells\u2019 options out of play by making the testosterone levels rise and fall rapidly,\u201d says Denmeade. Denmeade turned the idea in a clinical trial of testosterone as a prostate cancer drug therapy.\u201d<\/p>\n *** https:\/\/www.hopkinsmedicine.org\/news\/articles\/testosterone-as-a-drug<\/a><\/p>\n Boston Medical Group Telemedicine has TRT Programs<\/strong><\/p>\n “At first I was skeptical about this whole testosterone idea. I was not prepared for what was in store for me…It has taken some time to get the levels adjusted but there is no denying the effects of testosterone has had a huge positive effect on my life.”<\/strong><\/p>\n -Boston Medical Group Telemedicine Patient<\/strong><\/p>\n Testosterone is the key hormone produced by the Leydig cells of the testicles and is responsible for the normal growth and development of male organs and for maintenance of other sexual characteristics. Aside from sexuality, it also contributes to some essential body functions such as embryological development, facial hair development, brain function, body muscle mass, bone strength, red blood cells function and even mood and energy levels.<\/p>\n The range for normal testosterone level is 300-1100 ng\/dL. It is optimal for a man to get around 800- 1100 ng\/dL. When a man reaches his mid 30\u2019s, production of testosterone declines an estimate of 1% each year \u2013 10% in 10 years or even more. Greater decline in testosterone level can happen due to obesity, infectious diseases, excess of blood iron and inflammatory diseases.<\/p>\n Low testosterone level can post significant health risks and physical limitations such as decreased energy, low libido, decreased mental quickness and depression. If left untreated, it may lead to more serious health problems such as osteoporosis, muscle atrophy, alopecia and erectile dysfunction.<\/p>\n *** https:\/\/www.bostonmedicalgroup.com\/low-testosterone<\/a><\/p>\n Click here to read Part I: It’s Not Just About Muscles<\/a><\/p>\nHormone Therapy and Prostate Cancer<\/h2>\n
![\"\"](\"https:\/\/www.bostonmedicalgroup.com\/wp-content\/uploads\/2021\/05\/testosterone-p3-dr.png\")
<\/p>\n![\"\"](\"https:\/\/www.bostonmedicalgroup.com\/wp-content\/uploads\/2021\/05\/testosterone-p3-dr-2-e1620414451232.jpg\")
<\/p>\n![\"\"](\"https:\/\/www.bostonmedicalgroup.com\/wp-content\/uploads\/2021\/05\/testosterone-p3-3-e1620414672828.jpg\")
<\/p>\n